Alex Sparreboom, PhD
College of Pharmacy
Alex Sparreboom, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he seeks to improve the long-term outcome of patients by modulating the therapeutic window of widely used chemotherapeutics. His work studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters and translates the findings to clinical trials.Dr. Sparreboom is the co-holder of several U.S., European and world patents. One group of patents was secured for predicting responsiveness of a tumor to therapeutic treatment by correlating the CYP1B1 or ABCB1 genotype status of a tumor cell to the therapeutic treatment. Another group of patents was obtained for predicting a prognostic outcome of a subject suffering from androgen independent prostate cancer by determining the SLCO1B3 genotype status and correlating that to overall survival. Among his recent research is the development of transport modulators to be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with an emphasis on developing innovative pre-clinical model systems. Dr. Sparreboom has co-authored more than 50 articles appearing in such well-respected publications as Clinical Cancer Research, Journal of Clinical Investigation and Proceedings of the National Academy of Sciences USA. Additionally, he has shared his research in over 100 presentations to various organizations, including the American Association for Cancer Research, the American Society for Clinical Pharmacology and Therapeutics and the American Society of Clinical Oncology.